Category Archives: Regenerative Medicine

Dr. Natthapat Benz Minchaiynunt from Alpha Medical Clinic on his vision for the future of aesthetic services, mastering the PICO Laser, and offering clients nothing but the very best.

Known for impeccably precise treatments and top-of-the-line equipment, a visit to Alpha Medical Clinic Thailands largest private aesthetic clinic is unlike any other. Advanced technologies provide the highest standards of safety and quality, while welcoming VIP private rooms make the space reminiscent of a luxury hotel.

The true highlight, however, is the founder himself: Thailands first and only specialist with triple American Board certifications in Aesthetic Medicine (AAAM), Anti-Aging and Regenerative Medicine (ABAARM), and Laser Surgery (ABLS) and a Fellow in Aesthetic Medicine (FAM) Dr. Natthapat Benz Minchaiynunt. He is the most popular go-to specialist in Thailand for Picosecond Laser, with more than 500 patients a month coming only for this specific treatment. Prominent society faces book weeks ahead to be treated by him personally, and the clinic is ranked among Thailands top clinics for fillers.

Many things brought us to where we are today, Dr. Benz notes, our philosophy, knowledge and world-class techniques adapted from top professors around the world. He confesses that Alpha Medical Clinic was initially built for him to share his expertise with close friends and family, but over time he felt an ethical responsibility to open it to the public.

We started by inviting people we knew, he explains, they got much better results compared to other clinics, started referring us to one another through word of mouth, and thats how we grew. It really boils down to providing the best result for your clients.

In this case, the best is almost an understatement. Alpha Medical Clinic is home to some of the most advanced aesthetic equipment on the market, such as the Discovery Pico Laser 1.8GW. Very few of these machines exist in Thailand, as most hospitals and clinics use Discovery Pico Derm (Start) 1.3GW (which has less peak power and pulse energy), Thermage FLX, Thermage CPT, Ulthera SPT and other lasers.

Treatment plans are personalised to individual needs, identified through detailed consultations and a 3D augmented reality (AR) machine, which can scan under the inner skin (areas that are impossible for a general practitioner to be able to see). We are able to utilise all laser machines to their fullest potential. At such high power usage, with the special technique and technology we have, it is completely safe for the skin, with no side effects, and that also reduces the number of treatment sessions required, Dr. Benz explains. We also use it to simulate facial reshaping, whether its Thermage to reduce the cheek width by specific millimeters, or to lift the facial skin using Ulthera treatments.

While its common in Thailand to visit an aesthetic clinic with specific treatments in mind, a large part of Dr. Benzs role is advising his patients on the ideal course of action, which is not necessarily what they book an appointment for. Not every treatment is going to be the right one for you. My job is to make sure your face is suitable for a specific procedure, and that it will help you get the results youre looking for whether with laser, a face lift, or injections that are the most effective and safest.

Although advanced technology is central to Alpha Medical Clinic, Dr. Benz believes knowledge and expertise is what sets it apart. My expertise is my technique, which I gained through research, and combining what Ive learned from industry experts abroad. Aside from having the best technology, knowing how to use it, and which parameters to set, are just as important.

Such techniques range from a scab-free tattoo removal approach, to special methods for healing acne scars. Dr. Benz refers to this as combi- RF, where Pico Laser and Thermage are combined to effectively remove scarring, and smoothen the skin.

Picosecond Lasers are good for treating acne scars. Thermage is a non-invasive radiofrequency (RF) therapy that stimulates collagen production, lifting and changing your face structure. Combined, you can remove pimples, while evening out the skin.

The Pico Laser remains Alpha Medical Clinics top treatment, with Dr. Benz as the clinics laser expert. Pico Laser is the God of Skin Lasers amongst industry insiders, he remarks. If you know how to utilise its full potential, it can do anything, from reducing wrinkles, to removing melasma, freckles or stretch marks, and brightening your skin. Whatever the objective of our patients are a smooth skin without pores, or a clear skin our Pico laser is the answer.

His expertise makes Alpha Medical Clinic one of the only places where clients can enjoy visible, long-lasting results without side effects. Doctors are usually wary of administering heavier treatments because theyre worried about side effect such as melasma and PIH. However, I have a special technique that doesnt stimulate PIH and other side effects.

Today, Dr. Benz and his team of specialists continue raising the bar for aesthetic and laser services in Thailand, debunking misconceptions and providing clients with superior service. There are a lot of misunderstandings in this industry, he says. For example, people usually think that any doctor should be a filler and laser expert, but this is not true. Doctors who inject fillers or perform good laser therapies should be specialists very well trained in this field. Other countries, like the USA, have specific boards for Aesthetic Medicine and Cosmetic Laser Surgery. We dont have such certification in Thailand yet, but Im hoping that changes soon.

When asked about his future goals, Dr. Benz shares his plan to expand into cosmetic surgery and other departments. As with Alpha Medical Clinic, I want to ensure that everything we offer is of superior quality and well rounded.

To find out more, visit alphamedicalclinicthailand.com.

Excerpt from:
Meet the Experts: Dr. Natthapat Benz Minchaiynunt of Alpha Medical Clinic - Prestige Online Thailand

Dr. Cato T. Laurencin is the first professor from the University of Connecticut to be elected to the Academia Europaea for his outstanding achievements as a researcher, along with his scholarship and eminence in his field. Membership to the Academia Europaea is by invite only after peer nomination and competition.I am very honored to be elected to this Academy. This further shows the importance of the field of Regenerative Engineering worldwide and its ability to bring breakthrough results aimed at ultimately helping people, said Laurencin, University Professor at UConn and the Albert and Wilda Van Dusen Distinguished Professor of Orthopaedic Surgery at UConn School of Medicine.

This year, in addition to being honored by theAcademiaEuropaea, six additional academies across the world have elected Laurencin in the past 9 months: theEuropean Academy of Sciences, theSenegalese Academy of Science and Technology, theBenin Academy ofScience andArts, theIndian Academy of Sciences, and the Royal Academy of Engineering.

Laurencin also serves as CEO ofThe Connecticut Convergence Institute for Translation in Regenerative Engineeringat UConn Health and professor of chemical engineering, materials science and engineering, and biomedical engineering at UConn.

Laurencins seminal and singular accomplishments in tissue regeneration, biomaterials science, and nanotechnology, and regenerative engineering, a field he founded, have made him the foremost engineer-physician-scientist in the world. His breakthrough achievements have resulted in transformative advances in improving human life. His fundamental contributions to materials science and engineering include the introduction of nanotechnology into the biomaterials field for regeneration.

Laurencin has received singular honors in engineering, medicine, science and technology for his work. He is the first individual in history to receive both the oldest/highest award of the National Academy of Engineering (the Simon Ramo Founders Award) and one of the oldest/highest awards of the National Academy of Medicine (the Walsh McDermott Medal). The American Association for the Advancement of Science awarded Laurencin the Philip Hauge Abelson Prize given for signal contributions to the advancement of science in the United States. He is the recipient of the National Medal of Technology and Innovation, Americas highest honor for technological achievement, awarded by President Barack Obama in ceremonies at the White House

In recognition of his breakthrough achievements in Regenerative Engineering worldwide, the American Institute of Chemical Engineers created the Cato T. Laurencin Regenerative Engineering Founders Award.

The Academy is the Pan-European Academy of Sciences Humanities and Letters. The Academys members are scientists and scholars who collectively aim to promote learning, education and research. Founded in 1988, with more than 5,000 members which includes leading experts from the physical sciences and technology, biological sciences and medicine, mathematics, the letters and humanities, social and cognitive sciences, economics and the law. The Academy also publishes the international journal the European Review.

Academia Europaea advances and propagates excellence in scholarship in the humanities, law, the economic, social, and political sciences, mathematics, medicine, and all branches of natural and technological sciences anywhere in the world for the public benefit and for the advancement of the education of the public of all ages in the aforesaid subjects in Europe. The Academy includes seventy-two Nobel Laureates, several of whom were elected to the Academia before they received the prize.

I would like to congratulate you on having been successful in the competitive membership election process, wrote Marja Makarow, president of the Academia Europea in her award letter to Laurencin.

Laurencins election to the Academy will be honored at its October 2023 annual conference in Munich.

View post:
Dr. Cato T. Laurencin First from UConn Elected to the Academia Europaea - UConn Today - UConn

At the 18th International Conference of the Metabolomics Society, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics with a focus on unbiased Spatial Single-Cell Metabolomics (SSCM) for probing differential cellular phenotypes based on the metabolic signature of tissues and single cells.

Combining SSCM with the recently announced MALDI HiPLEX-IHC workflow enables in situ single cell immunometabolomics studies that integrate metabolomics-based immune reprogramming with targeted proteomics. This single-cell multiomics workflow is enabled by the new microGRID smartbeam 3D MALDI source for timsTOF fleX systems for sub-micron positioning for spatial resolution down to five micrometers (5 m), virtually eliminating any artifacts in the co-registration of MALDI molecular images with optical microscopy.

Single-cell technologies have revolutionized the understanding of heterogeneous biological processes underlying cancer, regenerative medicine, aging, and liver diseases. Studying cell-to-cell tissue variation enhances translational research, for example, in the development of better cancer research methods for the development of therapeutics targeting rare tumor cells.

Professor Theodore Alexandrov, Head of the Metabolomics Core Facility and Molecular Medicine Partnership Unit at the EMBL in Heidelberg, Germany, will lead a new project called SpaceM in the BioStudio Faculty of the BioInnovation Institute in Copenhagen, Denmark, focusing on single-cell metabolomics for drug discovery and precision medicine.

Dr. Alexandrov commented: We are in the process of developing the SpaceM technology for spatial single-cell metabolomics, developed at EMBL Heidelberg, into a platform for rapid drug discovery. As part of the BioStudio program at the BioInnovation Institute in Copenhagen, we will use a timsTOF fleX MALDI-2 imaging system for fast, sensitive, and specific in situ analyses of single cells to determine their metabolic states. In addition, the latest microGRID technology will provide us with the high spatial resolution needed to precisely interrogate single cells.

Bruker today also announced the next-generation of its advanced MetaboScape and TASQ software for metabolomic profiling and quantitation. MetaboScape 2022b now features integration of CCS-Predict Pro machine learning. Accurate and reproducible CCS values measured on the timsTOF platform can be matched to CCS values predicted from compound libraries or biotransformation algorithms, adding an orthogonal dimension for confident compound annotation.

TASQ 2022b complements the established target screening and quantitation functionality by a CCS-enabled isotope tracing workflow module. Data processing for large scale stable isotope tracer experiments is simplified as key algorithms such as the correction for naturally occurring isotopes and fractional contribution of isotopic labels are provided.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit http://www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005515/en/

Excerpt from:
Bruker is Ushering in the Age of Spatial Single-Cell Metabolomics - GuruFocus.com

Zhijian James Chen, Ph.D.

DALLAS June 16, 2022 UTSouthwestern researchers Zhijian James Chen, Ph.D., and Sihan Wu, Ph.D., are part of a team that has been awarded a Cancer Grand Challenges grant, a unique award that aims to solve some of cancers toughest problems by bringing together global teams with diverse areas of expertise.

The initiative, founded by Cancer Research UK and the National Cancer Institute, will provide 20 million pounds equivalent to about $25 million over five years to Drs. Chen and Wu and colleagues from the U.S., U.K., and Germany to learn more about a phenomenon known as extrachromosomal DNA (ecDNA) circular pieces of DNA that exist outside of a cells main DNA bound together in chromosomes.

Its a great honor to be part of this stellar team, but its also a large responsibility to be entrusted with a lot of resources to solve a difficult problem in cancer biology, said Dr. Chen, Professor of Molecular Biology and Director of the Center for Inflammation Research at UTSW, a Howard Hughes Medical Institute Investigator, and winner of the 2019 Breakthrough Prize in Life Sciences.

Sihan Wu, Ph.D.

Dr. Chen is one of the worlds leading investigators into innate immunity. His discovery of the cGAS (cyclic GMP-AMP synthase) enzyme, which triggers a pathway that activates the bodys immune system, has opened the door for development of drugs designed to modulate an immune response and fight diseases such as lupus and cancer.

Its a unique and unprecedented opportunity to conduct multi-disciplinary studies focusing on ecDNA, to understand how ecDNA-driven cancers interact with the immune system, said Dr. Wu, Assistant Professor at Childrens Medical Center Research Institute at UTSW.

Dr. Wu, a leading scientist in the ecDNA field, is one of the pioneers who revealed the physical shape and molecular functions of ecDNA in cancer, laying the foundation for the modern biology of ecDNA.

Dr. Chen and Dr. Wu plan to use the funds from Cancer Grand Challenges to better understand whether cGAS detects ecDNA. One of the mysteries of ecDNA in cancers, explained Dr. Chen, is why it doesnt trigger immune activity. The two scientists aim to discover what mechanisms cancer cells use to evade immune detection, which eventually could lead to new ways to treat cancers with immunotherapy.

Their team is being led by Paul Mischel, M.D., Professor of Pathology at Stanford University, and includes scientists from University of California San Diego, The Scripps Research Institute, Fred Hutchinson Cancer Center, New York University Langone Health, Jackson Laboratory for Genomic Medicine, University College London, Queen Mary University London, University of Cambridge, University College London, and Max Delbruck Center for Molecular Medicine and Charit Berlin.

Dr. Chen is the George L. MacGregor Distinguished Chair in Biomedical Science. Dr. Wu is a Cancer Prevention and Research Institute of Texas (CPRIT) scholar. Drs. Chen and Wu are both members of the Harold C. Simmons Comprehensive Cancer Center.

About UTSouthwestern Medical Center

UTSouthwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 26 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in more than 80 specialties to more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

About Childrens Medical Center Research Institute at UTSouthwestern

Childrens Medical Center Research Institute at UTSouthwestern (CRI) is a joint venture of UTSouthwestern Medical Center and Childrens Medical Center Dallas, the flagship hospital of Childrens Health. CRIs mission is to perform transformative biomedical research to better understand the biological basis of disease. Located in Dallas, Texas, CRI is home to interdisciplinary groups of scientists and physicians pursuing research at the interface of regenerative medicine, cancer biology and metabolism. For more information, visit:cri.utsw.edu. To support CRI, visit:give.childrens.com/about-us/why-help/cri/

Read the rest here:
UTSW researchers part of winning global team in Cancer Grand Challenges - UT Southwestern

Wilmington, Delaware, United States: According to Transparency Market Researchs latest report on the global regenerative medicine market for the historical period 20172018 and forecast period 20212028, increase in demand for customized regenerative medicine is projected to drive the global regenerative medicine market during the forecast period

Rise in Prevalence of Chronic Diseases, Genetic Disorders, and Cancer: Key Driver

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=419

Key Players Increased Investment in Research & Development of Regenerative Medicine

Get COVID-19 Analysis on Regenerative Medicine Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=419

Costly Treatment Associated with Regenerative Medicine

Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=419

Regenerative Medicine Market: Competition Landscape

More Trending Reports by Transparency Market Research

Dermal Fillers Market: https://www.transparencymarketresearch.com/dermal-fillers-market.html

Vascular Injury Treatment Market: https://www.transparencymarketresearch.com/vascular-injury-treatment-market.html

Hepatorenal Syndrome Treatment Market: https://www.transparencymarketresearch.com/hepatorenal-syndrome-treatment-market.html

Surgical Glue Market: https://www.transparencymarketresearch.com/surgical-glue-market.html

Ultrasound Gels Market: https://www.transparencymarketresearch.com/ultrasound-gel-market.html

Diabetic Foot Ulcers Treatment Market: https://www.transparencymarketresearch.com/diabetic-foot-ulcers-treatment-market.html

Menopausal Hot Flashes Market: https://www.transparencymarketresearch.com/menopausal-hot-flashes.html

Orthobiologics Market: https://www.transparencymarketresearch.com/orthobiologics-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read more from the original source:
Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market - BioSpace

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-501A in relapsed/refractory LBCL. The RMAT designation was based on the potential of ALLO-501A to address the unmet need for patients who have failed other therapies.

The designation for ALLO-501A supports the patient need for access to an off-the-shelf CAR T product that can be delivered faster, more reliably, and at greater scale, said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. Patients who are eligible for autologous CAR T therapy are often faced with treatment delays and manufacturing failures, placing them at risk for disease progression and disease-related complications. We look forward to initiating our pivotal trial on ALLO-501A and making this innovative product candidate readily available to patients.

Results from the ALPHA2 study were presented at an oral session of the American Society of Hematology (ASH) annual meeting in December 2021. Data support the potential of ALLO-501A to provide a safe and durable alternative to approved autologous CAR T therapies in CAR T nave patients.

Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the development and review processes for promising pipeline products, including cell therapies, that includes all the benefits of Fast Track and Breakthrough designation. An investigational cell therapy is eligible for RMAT designation if it is intended to treat, modify, reverse, or cure a serious or life-threatening disease; and preliminary clinical evidence indicates that the therapy has the potential to address unmet medical needs for that disease. Advantages of the RMAT designation include early interactions with FDA that may be used to discuss potential surrogate or intermediate endpoints and potential ways to satisfy post approval requirements.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visitwww.allogene.comand follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as predicts, believes, potential, proposed, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words that convey uncertainty of future events or outcomes to identify these forward- looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to progress the ALPHA2 trial of ALLO-501A, including initiating a pivotal clinical trial of ALLO-501A, which remains subject to further patient follow-up and discussions with the U.S. Food and Drug Administration; the ability to commercialize ALLO-501A; clinical outcomes, which may materially change as patient enrollment continues and more patient data become available; and the potential benefits of AlloCAR T. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with theSEC, including without limitation in its Form 10-Q for the quarter endedMarch 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Allogenes AlloCAR T programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

Source: Allogene Therapeutics, Inc.

Read more from the original source:
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma -...

China Regenerative Medicine International (HKG:8158) has had a rough three months with its share price down 12%. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Specifically, we decided to study China Regenerative Medicine International's ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

See our latest analysis for China Regenerative Medicine International

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) Shareholders' Equity

So, based on the above formula, the ROE for China Regenerative Medicine International is:

44% = HK$49m HK$112m (Based on the trailing twelve months to March 2022).

The 'return' is the profit over the last twelve months. So, this means that for every HK$1 of its shareholder's investments, the company generates a profit of HK$0.44.

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

First thing first, we like that China Regenerative Medicine International has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 8.1% which is quite remarkable. This likely paved the way for the modest 17% net income growth seen by China Regenerative Medicine International over the past five years. growth

Next, on comparing with the industry net income growth, we found that China Regenerative Medicine International's growth is quite high when compared to the industry average growth of 12% in the same period, which is great to see.

Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if China Regenerative Medicine International is trading on a high P/E or a low P/E, relative to its industry.

China Regenerative Medicine International doesn't pay any dividend, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.

In total, we are pretty happy with China Regenerative Medicine International's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company. Our risks dashboard would have the 2 risks we have identified for China Regenerative Medicine International.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Follow this link:
Declining Stock and Solid Fundamentals: Is The Market Wrong About China Regenerative Medicine International Limited (HKG:8158)? - Simply Wall St

DUBLIN, June 10, 2022 /PRNewswire/ -- The "Global Medical Collagen Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

The global medical collagen market indicates that it would register growth at a CAGR of 6.57% in the projected years from 2022 to 2028.

The growing public awareness about the benefits of collagen is a key factor fuelling the growth of the market. Besides, the rising demand for collagen from the medical devices industry is also aiding the market's growth. However, certain health-related issues that may occur as a result of collagen usage and a section of the population restricting the use of animal-derived products pose a challenge to this growth.

On the other hand, there is still a large demand for collagen-rich food & beverages from people across the globe, which presents a growth opportunity for the market. Moreover, the growth of the cosmetics industry also indicates the vast potential for market growth as collagen is used substantially in many of these products.

The global market for medical collagen covers North America, Europe, the Middle East and Africa, Latin America, and the Asia-Pacific.

North America was the leading market globally in 2021, and is estimated to continue its reign until the end of the forecast period. It is known for being a developed region in all aspects. Further, the people here are also becoming significantly aware and conscious about their health. This has led to an increased demand for collagen-based products among people in the US and Canada. Consumers are including collagen in their diet in the form of food, drinks, and supplements. These factors are contributing to the growth of the regional market.

The noteworthy players profiled in the medical collagen market are Lapi Gelatine, Symatese, Integra Life Sciences, Collagen Matrix Inc, DSM, Nippi Inc, Connoils LLC, Gelita, Jellagen, Stryker, Italgel, Darling Ingredients Inc, Tessenderlo Group, Weishardt, and Nitta Gelatin Inc.

Integra Life Sciences is a renowned industry leader in the field of medical technology. Some of its famous brands include MatriStem UBMT, Integra, MediHoney, and ICP Express, among others. The US-based company was founded in 1989 and is headquartered in Princeton, New Jersey. In FY 2020, Integra's revenue and total assets increased in the fourth quarter. In Jan 2021, Integra Life Sciences acquired the regenerative medicine company Acell Inc. Post this acquisition, the company has been serving its customers more efficiently by offering them collagen-based wound management solutions.

Key Topics Covered:

1. Global Medical Collagen Market - Summary

2. Industry Outlook2.1. Impact of Covid-19 on the Medical Collagen Industry2.2. Key Insights2.2.1. Significant Investment in Research and Development Activities 2.2.2. Evolving Healthcare Industry2.2.3. Launch of New Products Due to Increased Research2.3. Porter's Five Forces Analysis2.3.1. Threat of New Entrants2.3.2. Threat of Substitutes2.3.3. Bargaining Power of Buyers2.3.4. Bargaining Power of Suppliers2.3.5. Threat of Competitive Rivalry2.4. Key Impact Analysis2.4.1. Quality2.4.2. Side-Effects2.4.3. Product Effectiveness2.4.4. Price2.5. Market Attractiveness Index2.6. Vendor Scorecard2.7. Industry Components2.8. Regulatory Framework2.9. Key Market Strategies2.9.1. Acquisitions2.9.2. Product Launches2.9.3. Partnerships2.9.4. Business Expansions2.10. Market Drivers2.10.1. Increasing Demand from the Medical Devices Industry2.10.2. Growing Public Awareness 2.11. Market Challenges2.11.1. Health-Related Issues2.11.2. Consumers Limiting the Use of Animal-Based Products 2.12. Market Opportunities2.12.1. Growth of the Cosmetics Industry2.12.2. Rising Demand for Collagen-Rich Food & Beverages

3. Global Medical Collagen Market Outlook - by Source3.1. Bovine3.2. Porcine3.3. Other Sources

4. Global Medical Collagen Market Outlook - by Product4.1. Gelatine4.2. Hydrolyzed Collagen4.3. Native Collagen4.4. Other Products

5. Global Medical Collagen Market Outlook - by Application5.1. Wound Care5.2. Bone Grafts5.3. Tissue Scaffolds5.4. Cartilage Repair5.5. Hemostats5.6. Diagnostics5.7. Vascular Grafts5.8. Other Applications

6. Global Medical Collagen Market - Regional Outlook

7. Competitive Landscape7.1. Gelita7.2. Nitta Gelatin Inc7.3. Nippi Inc7.4. Italgel7.5. Weishardt7.6. Darling Ingredients Inc7.7. Lapi Gelatine7.8. Tessenderlo Group7.9. Dsm7.10. Collagen Matrix Inc7.11. Connoils LLC7.12. Integra Life Sciences7.13. Symatese7.14. Stryker7.15. Jellagen

8. Research Methodology & Scope

For more information about this report visit https://www.researchandmarkets.com/r/10kuec

Story continues

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Cision

View original content:https://www.prnewswire.com/news-releases/insights-on-the-medical-collagen-global-market-to-2028---rising-demand-for-collagen-rich-food--beverages-presents-opportunities-301565689.html

SOURCE Research and Markets

Originally posted here:
Insights on the Medical Collagen Global Market to 2028 - Rising Demand for Collagen-Rich Food & Beverages Presents Opportunities - Yahoo Finance

Injections of platelet-rich plasma (PRP) are commonly offered to men with erectile dysfunction (ED) by a variety of healthcare professionals at high cost, despite the lack of evidence-based guidelines to back its use or any standardized protocols or duration of treatment, according to a new study.

Investigators researched over 100 clinics in eight populous metropolitan areas of the United States and found that these injections were widely available. The mean cost of each injection was over $1500, and treatment ranged from one to an indefinite number of injections.

"The take-home message for patients is to approach purported 'miracle cures' with skepticism and realize that many cash-based treatments rely on salesmanship," senior author Sriram Eleswarapu, MD, PhD, assistant clinical professor of urology, University of California, Los Angeles, told theheart.org | Medscape Cardiology.

"Doctors and other healthcare workers should be mindful of the potential for medical harm and financial toxicity. Guidelines-conformant, evidence-based care should take precedence while investigational therapies like PRP are being studied in clinical trials," he said.

The study was published online May 26 in JAMA Network Open.

PRP, often called the "Priapus shot" or "P-shot," Eleswarapu said, "has emerged in a variety of medical and cosmetic applications, and there is some thought that PRP injections into the penis might be useful as a regenerative therapy of ED; however, there are no good data suggesting that PRP actually works for this purpose."

The American Urological Association (AUA) and the Sexual Medicine Society of North America have issued statements that PRP is an investigational treatment that should not be offered for payment, Eleswarapu points out. In fact, the AUA erectile dysfunction guideline states that men with ED "should undergo a thorough medical evaluation and offered a variety of proven treatment options, rather than investigational therapies."

Despite the absence of clinical trial data on PRP for ED, "many providers have begun to market this treatment and charge high fees, with no guarantee that it helps. Unfortunately, men are desperate for cures and are willing to pay for therapies with no proven benefit," he noted.

To "characterize the landscape" of PRP injection therapy for ED, the researchers used a "secret shopper" approach a market research method that involves using a script to inquire about products and pricing in service industries, they note.

Using an internet search, they identified 109 clinics that offered PRP for ED in eight major metropolitan areas (Atlanta, Boston, Dallas, Houston, Los Angeles, New York, Philadelphia, and Washington, DC). The researchers contacted the clinics via telephone and used a standardized script to request information about pricing, protocols, and clinician credentials.

Clinics that did not respond were excluded from the study, leaving 90 clinics for which data were available concerning pricing and treatment duration.

Of the providers, only 9% were urologists; 22% were not physicians and included chiropractors, integrative healthcare providers, naturopaths, nurse practitioners (NPs), and physician assistants (PAs). The most common providers were family medicine physicians (almost 14%), NPs (almost 14%), internal medicine practitioners (11%), and "unknown" or "other" providers (12%).

Other provider specialties included anesthesiology, emergency medicine, general surgery, obstetrics/gynecology, oncology, orthopedic surgery, plastic surgery, and physiatry.

Cost ranged from a mean price of $1367 (range, $350 $2500) in Los Angeles (n = 20 clinics) to $1580 ($1200 $1900) in Washington, DC (n = 5 clinics). Except for the clinics in Los Angeles, the mean price in all other areas was $1500.

The authors highlight the "substantial cost," lack of standardized protocol, and the high number of nonphysicians as well as physicians who had no training in male sexual dysfunction who administered these injections. The investigators state that the findings "suggest that guideline-nonconformant care has been driven by the consumerization of sexual health."

Commenting on the study for theheart.org | Medscape Cardiology, Ryan Terlecki, MD, professor and vice chair of urology, Wake Forest University School of Medicine, said it is "not surprising for those of us in practice to see what's taking place and that it is driven by financial benefit."

Many people in other areas of medicine have found that administering these injections is a "nice career change, and they can make a lot of money often cash-based with low stress and no insurance to file," said Terlecki, who was not involved with the study.

"The message for patients is 'buyer beware,' and for physicians, the message is that you can give these injections, and you can make a lot of money, but it doesn't appear necessarily to be ethical. Even when patients say that it worked, it might be a placebo response; but if you're going to get rich off a placebo response, is that ethical?"

He noted that there do not appear to be safety concerns regarding PRP injections for ED, since the cells being used are from the patient's own body.

"If you pay careful attention to skin preparation and how you handle the injections, there doesn't appear to be a huge risk to anything other than the wallet and perhaps faith in the medical community, in that the provider may potentially undermine legitimate attempts to determine whether something is of benefit scientifically."

No source of funding for the study was provided. Eleswarapu reports receiving personal fees from Metuchen Pharmaceuticals outside the submitted work. The other authors' disclosures are listed on the original article. Terlecki receives research funding from the Department of Defense and is a consultant for Boston Scientific; he also receives grant funding from Boston Scientific and is on its advisory board.

JAMA Netw Open. Published online May 26, 2022. Full text

For more from the heart.org | Medscape Cardiology, follow us on Twitter and Facebook.

More:
'P-Shot' for Erectile Dysfunction: Pricey and Without Proof - Medscape

Researchers from TU Wien have fabricated artificial human tissue on a chip using a multi-photon lithography technique which could eliminate the need for animal testing in the future.

The laser-based method enables the researchers to guide individual cells to specific locations within a hydrogel to form reproducible specialized tissue systems. These tissues can then be examined under precisely controlled conditions on a chip, holding promise for pharmaceutical research such as testing the efficacy of new drugs.

AM as an alternative to animal testing

In recent years, advances in bioprinting and tissue engineering technologies have offered increasingly viable alternatives to the use of animal models in experimental medical research. While viable patient-specific tissues for trialing the efficacy of drugs remain largely experimental for now, there is significant progress being made towards this goal.

For instance, bioprinter manufacturer CELLINK has pledged to advance its research into animal cruelty-free cellular testing models, while the University of Stuttgart is working on the development of microscale bioprinted skin models to trial the efficacy of cancer drugs.

Elsewhere, Fluicells Biopixlar platform is producing highly-complex neural models which could offer future applications for clinical drug screening, while UpNanos NanoOne Bio system is hoping to reduce the number of animal testing experiments with its 3D printed cell-culturing microstructures.

Most recently, the Institute of Bioengineering of Catalonia (IBEC) announced it was coordinating the EU-funded BRIGHTER project with the goal of developing new 3D bioprinting processes in order to reduce animal testing within the fields of tissue engineering and regenerative medicine.

Fabricating human tissue on a chip

Creating tissue structures in a lab often begins with living cells embedded in a hydrogel, usually a biocompatible material with properties very similar to those of biological tissue. Cells can migrate through the hydrogel and form a tissue, however the ability to precisely control this process and direct the cells towards a predetermined blueprint has so far been challenging.

By means of a laser, multi-photon lithography techniques can create intricate 3D microstructures with feature sizes as small as 100nm within photosensitive materials. The method has proven to be a suitable tool to precisely control the microenvironment of cells by altering the biochemical and biophysical properties of the hydrogel matrix they are encapsulated within.

According to Professor Aleksandr Ovsianikov, Head of the 3D Printing and Biofrabrication research group at TU Wien, the success of the teams technique is due to the addition of special molecules that change the physical properties of the hydrogel when activated by a laser.

At the precise point of contact with the laser, the hydrogel becomes softer and more permeable, enabling the creation of predetermined paths throughout the hydrogel along which cells can migrate.

The molecule couples to the network of the hydrogel, at this point the network becomes more hydrophilic, explained TU Wiens Simon Sayer. This changes the physical properties, and in this way it is possible to create a 3D pattern through which the cells can pass more easily than elsewhere.

As a result, the researchers were able to produce star-shaped or lattice-shaped cell structures within the hydrogel that mimic biological functions such as blood vessels. These tissues structures can then be placed on a chip of a few centimeters in size and be precisely supplied with specific nutrients or pharmaceutical compounds. How the tissues interact with each other can then be observed, allowing the team to gather important information about the effect of different drugs without the need for animal testing.

But this only works if we can precisely control the properties of these tissues, said Tommaso Zandrini, also of TU Wien. Firstly, these experiments need to be reproducible, so if you want several tissue samples with exactly the same microstructure, and secondly, you also need to be able to precisely connect the different samples for example, if youre studying the interaction between a small piece of heart muscle tissue and a small piece of liver tissue.

By leveraging their multi-photon lithography technique, the TU Wien team is able to accurately understand the interaction between different tissues as structures such as blood vessels can be printed in exactly the right place, while enabling the complexity of customized tissue samples to be significantly increased.

Further information on the study can be found in the paper titled: Guiding cell migration in 3D with high-resolution photografting, published in the Scientific Reports journal. The study is co-authored by S. Sayer, T. Zandrini, M. Markovic, J. Van Hoorick, S. Van Vlierberghe, S. Baudis, W. Holnthoner, and A. Ovsianikov.

Subscribe to the3D Printing Industry newsletterfor the latest news in additive manufacturing. You can also stay connected by following us onTwitterand liking us onFacebook.

Looking for a career in additive manufacturing? Visit3D Printing Jobsfor a selection of roles in the industry.

Subscribe to ourYouTube channelfor the latest 3D printing video shorts, reviews, and webinar replays.

Featured image showsleveraging their multi-photon lithography process, the researchers created star shaped patterns (left), into which the cells can grow (right). Image via TU Wien.

See the article here:
TU Wien 3D prints human tissue on a chip in bid to eliminate animal testing - 3D Printing Industry